Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD)
January 13, 2014 08:00 ET
|
Prosensa Holding N.V.
LEIDEN, Netherlands and LONDON, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to...
Prosensa to Present Corporate Overview at the 32nd Annual J.P. Morgan Healthcare Conference
January 07, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) announced
today that Hans GCP Schikan, Chief Executive Officer, will present
a corporate overview at the...
Prosensa Comments on Drisapersen Program Update
December 19, 2013 11:06 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
Prosensa Announces Extraordinary Shareholders Meeting to Appoint Dr. Georges Gemayel
December 10, 2013 09:15 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical need, today...
Prosensa and Partners Awarded Second European Consortium FP7 Research Grant
November 25, 2013 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands and Newcastle, UK, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical...
Prosensa Announces Third Quarter 2013 Financial Results and Recent Corporate Developments
November 18, 2013 08:00 ET
|
Prosensa Holding N.V.
LEIDEN, The Netherlands, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high...
Prosensa Awarded Best Biotech Pipeline 2013 at the Rare & Orphan Advocacy and Research (ROAR) Awards
November 15, 2013 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 15, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical need, has been...
Prosensa Holding N.V. to Webcast Conference Call Discussing 3rd Quarter 2013 Financial Results on November 18, 2013
November 11, 2013 08:09 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Monday, November...
Prosensa Enrolls 100th Patient to its Natural History Study of Duchenne Muscular Dystrophy
November 07, 2013 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on RNA-modulating therapeutics
for rare diseases with high...
Prosensa to Host Conference Call to Discuss Recent Drisapersen Data Presentations
October 03, 2013 16:30 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...